Cerecor Inc. (CERC) News
Filter CERC News Items
CERC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CERC News Highlights
- For CERC, its 30 day story count is now at 3.
- Over the past 24 days, the trend for CERC's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- RARE, MD and MG are the most mentioned tickers in articles about CERC.
Latest CERC News From Around the Web
Below are the latest news stories about Cerecor Inc that investors may wish to consider to help them evaluate CERC as an investment opportunity.
Avalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc.Name change underscores the Company’s transition to developing innovative targeted therapies in immunology, immuno-oncology, and rare genetic diseasesRobust pipeline of six product candidates advancing in development with eight ongoing clinical programsFour therapies with Rare Pediatric Disease Designation with each potentially eligible for a Priority Review Voucher upon approvalMultiple data readouts anticipated in the second half of 2021 WAYNE, Pa. and ROCKVILLE, Md., Aug. 26, 2021 (GLOBE NEWS |
Cerecor Reports Second Quarter 2021 Financial Results and Provides Business UpdatesAnnounced positive results for low-dose cohort of CERC-002 (1.0 mg/kg) in moderate-to-severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including anti-TNF alpha treatmentsAnnounced plans to explore CERC-002 in patients with moderate-to-severe ulcerative colitis refractory to anti-TNF alpha therapiesCompleted $35 million debt financing that extends cash runway and supports multiple clinical catalysts anticipated in the second half of 2021 ROCKVIL |
Cerecor Announces Drawdown of $10 Million Tranche under its Debt Financing Agreement with Horizon Technology FinanceAchieved performance milestone with positive initial results from its Phase 1b trial of CERC-002 in moderate-to- severe Crohn’s Disease who had previously failed three or more lines of biologics therapies, including anti-TNF alpha treatmentsROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for immunologic, immuno-oncologic and rare gen |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayGood morning! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayGreetings, trader! |
Cerecor's Crohn's Disease Candidate Shows Encouraging Response In Pretreated PatientsCerecor Inc (NASDAQ: CERC) announced initial results from a Phase 1b proof-of-concept study evaluating CERC-002 in adult patients with moderate to severe Crohn's disease (CD). CERC-002 is an investigational fully human anti-LIGHT (tumor necrosis factor superfamily member 14 (TNFSF14)) monoclonal antibody. Data includes for a low-dose cohort of CERC-002 (1.0 mg/kg) in moderate to severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including anti-TN |
Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease PatientsPositive results for low-dose cohort of CERC-002 (1.0 mg/kg) in moderate to severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including anti-TNF alpha treatmentsMean reduction in LIGHT levels of approximately 80% compared to baseline signify a dramatic and rapid reduction of LIGHT levels correlating to the pharmacodynamic effect of CERC-002Clinically meaningful endoscopic improvement in 75% (3/4) of subjects, as determined by colonoscopy (SES-CD |
15 Best Penny Stocks to Buy NowIn this article, we discuss the 15 best penny stocks to buy now. If you want to skip our detailed analysis of these companies, go directly to the 5 Best Penny Stocks to Buy Now. Many novice investors are bullish on penny stocks with growth potential for capital appreciation. All iconic stocks were once penny […] |
Cerecor Licenses Immune Checkpoint Program from Sanford Burnham Prebys Further Expanding Pipeline of Immunology and Immuno-oncology TargetsCerecor completes divestiture of non-core neurology pipeline assets as it increases its focus on immunology, immuno-oncology, and rare genetic disordersROCKVILLE, Md., June 23, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for immunology, immuno-oncology and rare genetic disorders, today announced that it has entered into an exclusive license agreement with Sanford Burnham Preb |
10 Best Biotech Penny Stocks to Buy NowIn this article, we discuss the 10 best biotech penny stocks to buy now. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Biotech Penny Stocks to Buy Now. The scintillating pace of technological advancement in the world over the past few decades has transformed the fortunes […] |